Follow up for Patients With Thyroid Cancer Planed for Radioiodine Scan or Treatment

The prevalence of thyroid cancer has increased in recent decades. Patients with thyroid cancer need to choose between Thyrogen® injection and Eltroxin® withdrawal before radioiodine therapy or scan. This is a prospective, observational study, aiming to observe the difference of metabolic profiles between patients choose Thyrogen® injection and Eltroxin® withdrawal.

Study Overview

• Status: Active, not recruiting
• Conditions: Thyroid Cancer
• Intervention / Treatment: Radiation: radioiodine

Detailed Description

1. Objective： To observe the difference between Thyogen® injection or Eltroxin® withdrawal on metabolic profile.
2. Background and method:： The prevalence of thyroid cancer has increased in recent decades. Patients with thyroid cancer need to choose between Thyrogen® injection and Eltroxin® withdrawal before radioiodine therapy or scan. This is a prospective, observational study, aiming to observe the difference of metabolic profiles between patients choose Thyrogen® injection and Eltroxin® withdrawal.

Inclusion ： Patient number: 500人

Inclusion criteria :

1. Patients with diagnosis of thyroid cancer。
2. Patients who need radioiodine therapy or scan。

Exclusion criteria:

1. Patients cannot cooperate with blood test.。
2. Patients cannot cooperate with radioiodine therapy。 Study design： Prospective, observational study。

Method： We will collect 20cc blood and 20 cc urine before and after radioiodine therapy during each visit (total 3 visits) and check lipid profiles, glucose profiles and inflammation markers. We will compare the difference between results of patients undergoing Thyrogen® injection and Eltroxin® withdrawal.

• Study Type: Observational
• Enrollment (Estimated): 107

Contacts and Locations

Study Locations

• Taiwan
  • Taichung, Taiwan, 407
    • Division of Endocrinology and Metabolism in Taichung Veterans General Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Patients with diagnosis of thyroid cancer

Description

Inclusion Criteria:

1. Patients with diagnosis of thyroid cancer。
2. Patients who need radioiodine therapy or scan。

Exclusion Criteria:

1. Patients cannot cooperate with blood test.。
2. Patients cannot cooperate with radioiodine therapy。

Study Plan

How is the study designed?

Design Details

• Observational Models: Cohort
• Time Perspectives: Prospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Zung's Self-reported depression scale	Depression symtpoms	1 month

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Brain-derived neurotrophic factor	BDNF	1 month
orexin	An associated factor for depression	1 month
Body composition	Fat component percentage to lean mass percentage ratio	1 months
VCAM-1	adhesion molecules	1 months
CRP	inflammation marker	1 months
Metabolic syndrome	The number of conponents for metabolic syndrome	1 months
Insulin resistance	HOMA-IR	1 month

Collaborators and Investigators

• Sponsor: Taichung Veterans General Hospital

Study record dates

Study Major Dates

• Study Start (Actual): June 6, 2018
• Primary Completion (Estimated): June 30, 2028
• Study Completion (Estimated): June 30, 2030

Study Registration Dates

• First Submitted: May 24, 2018
• First Submitted That Met QC Criteria: August 8, 2018
• First Posted (Actual): August 10, 2018

Study Record Updates

• Last Update Posted (Actual): May 1, 2026
• Last Update Submitted That Met QC Criteria: April 27, 2026
• Last Verified: April 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Endocrine System Diseases; Neoplasms by Site; Neoplasms; Endocrine Gland Neoplasms; Head and Neck Neoplasms; Thyroid Diseases; Thyroid Neoplasms; Iodine-131
• Other Study ID Numbers: CE18104A

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No